The DREAM trial

Lancet

Volumn 368, Issue 9552, 2006, Pages 2050-

  Lubsen, Jacobus ^a   Poole Wilson, Philip A ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RAMIPRIL; ROSIGLITAZONE;

CLINICAL TRIAL; DEATH; DIABETES MELLITUS; FACTORIAL DESIGN; FOLLOW UP; HUMAN; INCIDENCE; LETTER; MORTALITY; PRIORITY JOURNAL;

EID: 33845212859     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69828-0     Document Type: Letter

References (2)

1. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
2. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562